Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs

被引:257
作者
Abramson, MA [1 ]
Sexton, DJ [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
关键词
D O I
10.1086/501641
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To determine the attributable hospital stay and costs for nosocomial methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S aureus (MRSA) primary bloodstream infections (BSIs). DESIGN: Pairwise-matched (1:1) nested case-control study. SELLING: University-based tertiary-care medical center. PATIENTS: Patients admitted between December 1993 and March 1995 were eligible. Cases were defined as patients with a primary nosocomial S aureus BSI; controls were selected according to a priori matching criteria. MEASUREMENTS: Length of hospital stay and total and variable direct costs of hospitalization. RESULTS: The median hospital stay attributable to primary nosocomial MSSA BSI was 4 days, compared with 12 days for MRSA (P=.023). Attributable median total cost for MSSA primary nosocomial BSIs was $9,661 versus $27,083 for MRSA nosocomial infections (P=.043). CONCLUSION: Nosocomial primary BSI due to S aureus significantly prolongs the hospital stay. Primary nosocomial BSIs due to MRSA result in an approximate threefold increase in direct cost, compared with those due to MSSA (Infect Control Hosp Epidemiol 1999;20:408-411).
引用
收藏
页码:408 / 411
页数:4
相关论文
共 21 条
[1]  
BANERJEE SN, 1991, AM J MED S3B, V91, P86
[2]   EPIDEMIOLOGIC STUDIES OF AN OUTBREAK OF NOSOCOMIAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS INFECTIONS [J].
BOYCE, JM ;
LANDRY, M ;
DEETZ, TR ;
DUPONT, HL .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1981, 2 (02) :110-116
[3]   COMPARATIVE EFFICACY OF AMOXICILLIN-CLAVULANATE, CLOXACILLIN, AND VANCOMYCIN AGAINST METHICILLIN-SENSITIVE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN RATS [J].
CANTONI, L ;
WENGER, A ;
GLAUSER, MP ;
BILLE, J .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (05) :989-993
[4]   AMPICILLIN, SULBACTAM, AND RIFAMPIN COMBINATION TREATMENT OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN RABBITS [J].
CHAMBERS, HF ;
KARTALIJA, M ;
SANDE, M .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :897-902
[5]   HONG-KONG STRAINS OF METHICILLIN-RESISTANT AND METHICILLIN-SENSITIVE STAPHYLOCOCCUS-AUREUS HAVE SIMILAR VIRULENCE [J].
FRENCH, GL ;
CHENG, AFB ;
LING, JML ;
MO, P ;
DONNAN, S .
JOURNAL OF HOSPITAL INFECTION, 1990, 15 (02) :117-125
[6]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[7]   A COMPARISON OF CLINICAL VIRULENCE OF NOSOCOMIALLY ACQUIRED METHICILLIN-RESISTANT AND METHICILLIN-SENSITIVE STAPHYLOCOCCUS-AUREUS INFECTIONS IN A UNIVERSITY HOSPITAL [J].
HERSHOW, RC ;
KHAYR, WF ;
SMITH, NL .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1992, 13 (10) :587-593
[8]   EFFECT OF SOURCE OF MUELLER-HINTON AGAR ON DETECTION OF OXACILLIN RESISTANCE IN STAPHYLOCOCCUS-AUREUS USING A SCREENING METHODOLOGY [J].
HINDLER, JA ;
WARNER, NL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1987, 25 (04) :734-735
[9]   BETA-LACTAM-BETA-LACTAMASE-INHIBITOR COMBINATIONS ARE ACTIVE IN EXPERIMENTAL ENDOCARDITIS CAUSED BY BETA-LACTAMASE-PRODUCING OXACILLIN-RESISTANT STAPHYLOCOCCI [J].
HIRANO, L ;
BAYER, AS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :685-690
[10]   COMBINATION ANTIMICROBIAL THERAPY FOR STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN PATIENTS ADDICTED TO PARENTERAL DRUGS AND IN NON-ADDICTS - A PROSPECTIVE-STUDY [J].
KORZENIOWSKI, O ;
SANDE, MA .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (04) :496-503